Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84970 trials found · Page 41 of 4249
-
New hope for babies with SMA: drug trial aims to boost motor skills
Disease control Recruiting nowThis double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion…
Phase: PHASE2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
New 'Living Drug' trial offers hope for Tough-to-Treat cancers
Disease control Recruiting nowThis study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic …
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New drug trial aims to halt devastating nerve attack in GBS patients
Disease control Recruiting nowThe goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Major trial aims to put the brakes on Parkinson's
Disease control Recruiting nowParkinson's disease (PD) is currently the fastest-growing neurological condition globally. It is projected to affect 172,000 people in the UK by 2030,with the current annual cost to the country being \~£3.6 billion. The disease progressively impairs physical abilities, leading to…
Phase: PHASE3 • Sponsor: University College, London • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Custom mRNA vaccine aims to stop liver Cancer's return
Disease control Recruiting nowiNeo-Vac-R01, a personalized neoantigen-based mRNA therapeutic technology for tumors, is a customized neoantigen mRNA injectable formulation developed by collecting patients' tumor tissues and peripheral blood, screening appropriate neoantigens via high-throughput sequencing, and…
Phase: PHASE1, PHASE2 • Sponsor: Yinghua Xu • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New weapon against aggressive breast cancer enters major trial
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, a…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
Scientists test One-Time gene fix for 'Bubble Boy' disease
Disease control ENROLLING_BY_INVITATIONBackground: X-Linked Chronic Granulomatous Disease (X-CGD) is caused by a gene mutation that makes the immune system to not work properly. Researchers want to see if a lentiviral gene transfer treatment will have the ability to make the patient s immune system more normal, in pa…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
New bladder cancer device trial offers hope when standard treatment fails
Disease control Recruiting nowThe main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
Engineered immune cells take aim at deadly brain cancer
Disease control Recruiting nowThe purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
New hope for Tough-to-Treat lung cancer: experimental combo enters final testing phase
Disease control Recruiting nowThis is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the lo…
Phase: PHASE3 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New attack on lung cancer: combining immunotherapy with targeted local treatments
Disease control Recruiting nowFirst-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
First human trial of 'Tianasen' offers hope for kids with devastating genetic disorder
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy and safety of the investigational drug ASO-GNAO1 (Tianasen) in pediatric patients with c.607G\>A mutation in the GNAO1 gene associated with epilepsy and neurodevelopmental disorder. The main questions it aims to answer a…
Phase: PHASE1, PHASE2 • Sponsor: Pirogov Russian National Research Medical University • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Race to cut deaths from 'Fungal' pneumonia in vulnerable patients
Disease control Not yet recruitingPneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%. Reducing mortality from PJP is crucial for improving outcomes in critically ill non-HIV immunocompromised patients and allevia…
Phase: PHASE3 • Sponsor: Qingyuan Zhan • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New hope for tough pancreatic cancer: major trial tests drug combo
Disease control Recruiting nowThe goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
AI app aims to save lives by getting heart attack drugs to patients faster
Disease control Recruiting nowThe aim of the study is to elucidate whether guiding by a novel artificial intelligence assisted mobile application can improve the clinical outcomes of patients in whom "guide wire passing through the lesion" could not be achieved within 120 min after diagnosis of STEMI, compare…
Phase: NA • Sponsor: Shenyang Northern Hospital • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of …
Phase: PHASE3 • Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Double the shock to restart the heart: new trial aims to save more lives
Disease control Recruiting nowSome of the patients affected by Out-of-hospital cardiac arrest (OHCA) with ventricular fibrillation (VF)/ventricular tachycardia (VT) do not respond to initial defibrillation. The survival decreases with number of defibrillations required to terminate VF/VT. In 2022, one prospec…
Phase: PHASE2, PHASE3 • Sponsor: Gabriel Riva • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
New hope for Tough-to-Treat kidney cancer
Disease control Recruiting nowThe purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on…
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
New Triple-Threat treatment tested to shrink rectal tumors before surgery
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC). The hypothesis is that the addition of immunotherapy (PD-1 inhibitor) can…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Apr 06, 2026 14:15 UTC
-
Scientists test 'Vaccinal Effect' to free HIV patients from daily pills
Disease control Recruiting nowThere is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma. A new therapy, broadly neutralising antibodies, (bNAbs), may work as well as ART…
Phase: PHASE2 • Sponsor: University of Oxford • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC